Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718331 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL9641232 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| SCHEMBL10985870 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| SCHEMBL27864513 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| SCHEMBL7511792 | 0.79 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| SCHEMBL21137978 | 0.79 | SLC1A5 (0.41) | SMN1; SMN2NPC1RAB9ACYP1A2ALDH1A1 | |
| SCHEMBL6658582 | 0.79 | SLC1A5 (0.41) | SMN1; SMN2NPC1RAB9ACYP1A2ALDH1A1 | |
| SCHEMBL15156598 | 0.78 | PTPRA (0.42) | SMN1; SMN2NPC1RAB9ACYP1A2ALDH1A1 | |
| SCHEMBL28426909 | 0.77 | P4HTM (0.44) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 | |
| Methyl Alcohol SCHEMBL11294525 | 0.77 | PTPRA (0.41) | SMN1; SMN2NPC1RAB9ACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988312-B | Polyamide acid ester, preparation method, negative polyimide composition and application | 深圳先进技术研究院 | 2023-04-11 | — | — | CN | claimed |
| US-20210206835-A1 | Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related Thereto | NATIONAL SCIENCE FOUNDATION | 2021-07-08 | — | — | US | claimed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | claimed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | claimed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | claimed |
| CN-101495502-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1179056-B1 | MIXED-BED SOLID PHASE AND ITS USE IN THE ISOLATION OF NUCLEIC ACIDS | PROMEGA CORP (US) | 2004-07-28 | — | — | EP | claimed |
| JP-2002543980-A | — | — | 2002-12-24 | — | — | JP | claimed |
| WO-2000070041-A1 | MIXED-BED SOLID PHASE AND ITS USE IN THE ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | claimed |
| US-5959123-A | REACATING SUBSTITUTED AMINO ACID WITH 3-AMINO-4-SUBSTITUTED-AZETIDINE-2-ONE COMPOUND TO FORM 3, 4-DISUBSTITUTED-AZETIDINE-2-ONE COMPOUND; USEFUL FOR TREATING MUSCULAR DYSTROPHY, ARTHRITIS, VIRAL AND PARASITIC INFECTIONS | SYNPHAR LABORATORIES, INC. (CA) | 1999-09-28 | — | — | US | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997011958-A1 | PROTEIN SIGNATURE ANALYSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0656904-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR INC. (US) | 1995-06-14 | — | — | EP | claimed |
| EP-0606222-A1 | CYCLIC HEXAPEPTIDES AS TACHYQUININ ANTAGONISTS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1994-07-20 | — | — | EP | claimed |
| WO-1993024526-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR, INC. (US) | 1993-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | SMN1; SMN2 2751/4885NPC1 146/4885RAB9A 2307/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | SMN1; SMN2 631/4885NPC1 3199/4885RAB9A 1569/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | SMN1; SMN2 3157/4885NPC1 132/4885RAB9A 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.